Actively Recruiting
A Randomised Paired Design Study of Texture and Colour Enhancement Imaging (TXI) Versus High-definition White Light Endoscopy
Led by London North West Healthcare NHS Trust · Updated on 2026-04-13
219
Participants Needed
1
Research Sites
172 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Texture and Colour Enhancement Imaging (TXI) improves texture, brightness, and colour in white-light endoscopy to highlight subtle tissue differences. Now available through the EVIS X1 system, early evidence suggests potential value in IBD. Studies show that TXI may help predict ulcerative colitis relapse and performs comparably to dye chromoendoscopy in detecting lesions, though no randomised data exist for dysplasia detection in IBD surveillance. We therefore propose a randomised paired study comparing TXI with high-definition white-light endoscopy for dysplasia detection in IBD surveillance.
CONDITIONS
Official Title
A Randomised Paired Design Study of Texture and Colour Enhancement Imaging (TXI) Versus High-definition White Light Endoscopy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 16 years old with inflammatory bowel disease undergoing surveillance colonoscopy
- Patients with Crohn's disease (L2/L3 Montreal classification) involving more than 50% of the colon
- Patients with ulcerative colitis with extensive or left-sided disease (E3 or E2 Montreal classification) for at least 8 years or with primary sclerosing cholangitis alongside IBD
You will not qualify if you...
- Disease duration less than 8 years unless diagnosed with primary sclerosing cholangitis
- Incomplete colonoscopy
- Boston Bowel Preparation Scale (BBPS) score less than 6 or less than 2 in any colon segment
- Mayo Endoscopic Score (MES) 2 or higher, or Simple Endoscopic Score for Crohn's Disease (SES-CD) 2 or higher, or stenosis longer than 10 cm above the rectum
- Previous colorectal surgery
- Low platelet count (less than 50) or blood clotting problems preventing biopsy
- Anticoagulation medication not properly stopped before the procedure (must be stopped at least the morning of the procedure)
- Pregnancy
- Unable or unwilling to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Central Middlesex Hospital
London, United Kingdom, NW10 7NS
Actively Recruiting
Research Team
J
Jonathan Landy, Consultant Gastroenterologist
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here